ProQR Therapeutics (PRQR) Stock Forecast & Price Target

ProQR Therapeutics is supported by early proof-of-concept for AX-0810, with target engagement in healthy volunteers validating its Axiomer ADAR editing platform and NTCP modulation strategy, while human genetics around congenital NTCP deficiency provide a compelling safety rationale for lowering toxic bile acids. The company’s preclinical AX-0811 package also looks stronger, showing 67% lower hepatocyte bile acid levels, a 67% better histological cholestasis score, and modeled 40% to 65% liver editing with a projected 3-plus-month half-life, which could strengthen its cholestatic disease franchise. Although the $50 million offering of 27.6 million shares at $1.81 and $9.2 million private placement increase dilution, they extend the operational runway from mid-27 into 2H28 and fund a pipeline with important readouts in January 2027, 1H 2027, and mid-2028.

ProQR Therapeutics is viewed negatively because its business remains highly dependent on clinical execution in rare-disease RNA programs while facing a real risk of continued cash burn and future capital raises that could dilute shareholders. The company also faces significant regulatory, safety, and patient-enrollment hurdles, including uncertain validation of surrogate endpoints and the possibility that the FDA or EMA may narrow or reject indications. On top of that, strong competition from better-capitalized biotechnology and pharmaceutical peers, plus unresolved intellectual property and patent-defense risk, weakens the durability of its long-term value proposition.